Open AccessVaried presentation of post Covid mucormycosis in a tertiary care centre in Northern India
Author(s) -
Kafil Akhtar,
Neda Ahsan,
Mazhar Fahim,
Fatma Lubna,
Zohra Nahid Hashmi,
Saquib Anwer
Publication year - 2022
Publication title -
ip archives of cytology and histopathology research
Language(s) - English
Resource type - Journals
eISSN - 2581-5725
pISSN - 2456-9267
DOI - 10.18231/j.achr.2022.004
Subject(s) - mucormycosis , nose , medicine , retrospective cohort study , tertiary care , aspergillosis , dermatology , paranasal sinuses , surgery , immunology
: To study the cytomorphological presentation of post covid mucormycosis. A retrospective observational study was conducted at a tertiary care center in Northern India for a period of six months, in patients with post covid mucormycosis. The study included 50 cases with post covid mucormycosis. Males with 28 cases (56.0%) were more commonly affected than females. Nose comprising of 36 cases (72.0%) was the most commonly affected area, with nasal cavity showing 24 cases (48.0%) being most common site within the nose. 36 cases (72.0%) were positive exclusively for Mucormycosis. 10.0% cases of mucor showed superadded bacterial infection. Candida was seen in 03 cases (6.0%) and aspergillosis in 02 cases (4.0%). There were 6.0% cases of mucormycosis with associated chronic osteomyelitis. All the patients had a history of steroid use throughout their coronavirus treatment. A rare but fatal fungal infection (mucormycosis) has a strong association with covid-19 infection, in active as well as recovered patients, particularly in those with co-morbid medical conditions and treated with high doses of corticosteroids.